Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients

Niculescu et al., NCT04681001, NCT04681001, Aug 2021
300 participant iota-carrageenan prophylaxis RCT with results not reported over 4 years after completion.
Authors indicate that there were no SARS-CoV-2 infections in either group. The trial record also suggests there was no placebo group, with both groups receiving a nasal spray.
Niculescu et al., 30 Aug 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Austria, trial NCT04681001 (history). Contact: iulia.niculescu@gesundheitsverbund.at, eva.prieschl-grassauer@marinomed.com, nicole.unger-manhart@marinomed.com, arschang.valipour@gesundheitsverbund.at, waltraud.huf@gesundheitsverbund.at.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit